Drug-Coated Balloons for Coronary Artery Disease Global Market Opportunities and Strategies to 2035

This report describes and explains the drug-coated balloons for coronary artery disease market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global drug-coated balloons for coronary artery disease market reached a value of nearly $494.2 million in 2025, having grown at a compound annual growth rate (CAGR) of 14.8% since 2020. The market is expected to grow from $494.2 million in 2025 to $820.7 million in 2030 at a rate of 10.7%. The market is then expected to grow at a CAGR of 9.8% from 2030 and reach $1.31 billion in 2035.

Growth in the historic period resulted from the rising prevalence of coronary artery disease (CAD), higher exposure to smoking and air pollution, growing prevalence of hypertension and dyslipidemia and increasing health-insurance coverage. Factors that negatively affected growth in the historic period were competition from alternative therapies and shortage of skilled professionals.

Going forward, growing government funding for cardiovascular programs, increasing burden of diabetes and obesity, increasing rates of sedentary lifestyle and unhealthy diets and growth of private hospital networks will drive the growth. Factors that could hinder the growth of the drug-coated balloons for coronary artery disease market in the future include limited patient awareness of DCB treatment option lack of universal guideline support, and impact of trade war and tariffs.

The drug-coated balloons for coronary artery disease market is segmented by drug type into paclitaxel-coated DCBs and limus-coated DCBs. The paclitaxel-coated DCBs market was the largest segment of the drug-coated balloons for coronary artery disease market segmented by drug type, accounting for 96% or $474.5 million of the total in 2025. Going forward, the limus-coated DCBs segment is expected to be the fastest growing segment in the drug-coated balloons for coronary artery disease market segmented by drug type, at a CAGR of 12.7% during 2025-2030.

The drug-coated balloons for coronary artery disease market is segmented by end user into hospitals, cardiac catheterization labs, ambulatory surgical centers and other end-users. The hospitals market was the largest segment of the drug-coated balloons for coronary artery disease market segmented by end user, accounting for 51.1% or $252.8 million of the total in 2025. Going forward, the cardiac catheterization labs segment is expected to be the fastest growing segment in the drug-coated balloons for coronary artery disease market segmented by end user, at a CAGR of 14.1% during 2025-2030.

Western Europe was the largest region in the drug-coated balloons for coronary artery disease market, accounting for 55.7% or $275.4 million of the total in 2025. It was followed by Asia Pacific, North America and then the other regions. Going forward, the fastest-growing regions in the drug-coated balloons for coronary artery disease market will be Africa and Middle East where growth will be at CAGRs of 19.1% and 18.4% respectively. These will be followed by Latin America and North America where the markets are expected to grow at CAGRs of 18% and 14.6% respectively.

The global drug-coated balloons for coronary artery disease market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 81.98% of the total market in 2024. B. Braun Melsungen AG was the largest competitor with a 17.00% share of the market, followed by Boston Scientific Corporation with 13.69%, BIOTRONIK SE & Co. KG with 12.99%, Cordis Corporation (MedAlliance), with 11.94%, Meril Life Sciences Pvt. Ltd., with 8.21%, Acotec Scientific Holdings., Ltd. with 7.91%, Medtronic plc with 3.47%, Blue Sail Medical with 2.38%, OrbusNeich Medical Company Ltd. with 2.24% and MicroPort Scientific Corporation with 2.15%.

The top opportunities in the drug-coated balloons for coronary artery disease markets segmented by drug type will arise in the paclitaxel-coated DCBs segment, which will gain $310.3 million of global annual sales by 2030. The top opportunities in the drug-coated balloons for coronary artery disease markets segmented by end user will arise in the cardiac catheterization labs segment, which will gain $137.7 million of global annual sales by 2030. The drug-coated balloons for coronary artery disease market size will gain the most in the USA at $68.6 million.

Player-adopted strategies in the drug-coated balloons for coronary artery disease market include focus on enhancing its business operations through new launches, new approvals and product development.

Market-trend-based strategies for the drug-coated balloons for coronary artery disease market include emergence of sirolimus-eluting drug-coated balloons as advanced solutions for coronary intervention, expansion of clinical studies evaluating drug-coated balloons against standard care in coronary interventions and advancement of next-generation coronary drug-coated balloons (DCBs) for broader lesion treatment.

To take advantage of the opportunities, the analyst recommends the drug-coated balloons for coronary artery disease companies to focus on sirolimus-based innovation backed by clinical evidence, focus on large-scale comparative evidence to expand clinical adoption, focus on next-generation DCB versatility across lesion types, focus on dual-track DCB portfolios balancing scale and innovation, focus on channel expansion into specialized and outpatient cardiac care, focus on value-based and setting-specific pricing discipline, focus on evidence-led clinical promotion to drive adoption, focus on procedure-focused promotion across care settings, focus on shifting growth toward specialized and outpatient care settings.

This product will be delivered within 3-5 business days.